Transthyretin Amyloidosis

1
Pipeline Programs
6
Companies
5
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Alnylam Pharmaceuticals
2 programs
1
Computer algorithm for ATTRPhase 11 trial
99mTc-pyrophosphate ScintigraphyN/A
Active Trials
NCT04569903Withdrawn0Est. Feb 2025
BridgeBio Pharma
BridgeBio PharmaCA - Palo Alto
1 program
99mTc-pyrophosphate ScintigraphyN/A1 trial
Active Trials
NCT05577819Recruiting515Est. Dec 2026
Pfizer
PfizerNEW YORK, NY
1 program
99mTc-pyrophosphate ScintigraphyN/A
C
CENTOGENEGermany - Rostock
1 program
Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)N/A1 trial
Active Trials
NCT02713880Withdrawn0Est. Dec 2019
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
Phenotyping and Characterization of wtATTR-CM (TRACE 1)N/A1 trial
Active Trials
NCT06291805Recruiting120Est. Dec 2025
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Treatment of transthyretinN/A1 trial
Active Trials
NCT06465810Recruiting1,850Est. Dec 2031

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Alnylam PharmaceuticalsComputer algorithm for ATTR
AstraZenecaTreatment of transthyretin
Novo NordiskPhenotyping and Characterization of wtATTR-CM (TRACE 1)
BridgeBio Pharma99mTc-pyrophosphate Scintigraphy
CENTOGENEBiomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)

Clinical Trials (5)

Total enrollment: 2,485 patients across 5 trials

NCT04569903Alnylam PharmaceuticalsComputer algorithm for ATTR

Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records

Start: Aug 2022Est. completion: Feb 20250
Phase 1Withdrawn
NCT06465810AstraZenecaTreatment of transthyretin

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Start: Jun 2024Est. completion: Dec 20311,850 patients
N/ARecruiting
NCT06291805Novo NordiskPhenotyping and Characterization of wtATTR-CM (TRACE 1)

Phenotyping and Characterization of wtATTR-CM (TRACE 1)

Start: Feb 2024Est. completion: Dec 2025120 patients
N/ARecruiting
NCT05577819BridgeBio Pharma99mTc-pyrophosphate Scintigraphy

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

Start: Oct 2020Est. completion: Dec 2026515 patients
N/ARecruiting
NCT02713880CENTOGENEBiomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)

Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)

Start: Aug 2018Est. completion: Dec 20190
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 2,485 patients
6 companies competing in this space